Paeds · neurology-neurodisability-and-neuromuscular
Neurodegenerative and leukodystrophy disorders
Also known as Leukodystrophies · Inherited white-matter disorders · Genetic leukoencephalopathies · Dysmyelinating disorders · Metabolic neurodegeneration
A fellowship approach to the child with an inherited neurodegenerative white-matter disorder. Read the brain MRI pattern - the symmetric confluent change of metachromatic leukodystrophy, the contrast-enhancing parieto-occipital lesion of cerebral X-linked adrenoleukodystrophy, the tigrid stripes, the diffuse hypomyelination of Pelizaeus-Merzbacher, the vanishing white matter of eIF2B disease, the anterior-temporal cysts of megalencephalic leukoencephalopathy, and the calcification and atrophy of Aicardi-Goutieres - to generate a mechanism-based differential across the lysosomal, peroxisomal, hypomyelinating and astrocytopathic groups, and to drive a tiered workup anchored on MRI, biochemistry and genomic sequencing that identifies the disorders whose only therapy window closes before symptoms begin - the cerebral adrenoleukodystrophy that needs urgent transplant and the presymptomatic metachromatic leukodystrophy and Krabbe disease that newborn screening now lets us treat.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- A boy aged four to ten years with new behavioural change, school decline, seizures or adrenal insufficiency and a contrast-enhancing parieto-occipital splenium-based white-matter lesion on brain MRI has cerebral X-linked adrenoleukodystrophy - the inflammatory phase progresses rapidly and haematopoietic stem cell transplant is an emergency that works only if the Loes score is still low
- An infant with loss of milestones, progressive spasticity and a tigrid (leopard) pattern of symmetric periventricular white-matter change has metachromatic leukodystrophy - late-infantile disease is aggressive and gene therapy or transplant works only when given presymptomatically
- An irritable, hypertonic infant with feeding difficulty, unexplained fever and optic atrophy in the first six months has infantile Krabbe disease - haematopoietic stem cell transplant helps only presymptomatic neonates identified by newborn screening
- A child whose white matter rarefies and cavitates on serial MRI, with abrupt deterioration after fever, minor head trauma or fright, has vanishing white matter disease - deterioration is triggered by stress and there is no curative therapy
- An infant with basal-ganglia calcification, cerebral atrophy and a chronic CSF lymphocytosis mimicking congenital infection has Aicardi-Goutieres syndrome - an interferonopathy, now increasingly treated with JAK inhibitors
- A macrocephalic, hypotonic infant of Ashkenazi Jewish ancestry with diffuse spongiform white-matter change and a towering magnetic-resonance-spectroscopy N-acetylaspartate peak has Canavan disease
- Never accept a degenerative label for a leukodystrophy until the treatable inflammatory cause - cerebral adrenoleukodystrophy - has been actively excluded with a contrasted brain MRI, because transplant works only in the early window
Life stages
Care settings
Clinical exam formats
Board mappings
- General and Community Paediatrics
- Growth and Development
- Neurology and Neurodisability
- Neurology - recognise and investigate inherited leukodystrophies and neurodegenerative white-matter disorders
- Neurodisability - coordinate multidisciplinary and surveillance care for the child with a leukodystrophy
- Metabolic Medicine - interpret very-long-chain fatty acids, lysosomal enzymes and newborn-screening results
- Genetics - request and interpret genomic sequencing and counsel recurrence risk
- Neurology 13-15
- Metabolic Medicine 1-3
- Clinical Applications
- Long Cases
- Short Cases
- 9. Neurology: neurodegenerative and white-matter disorders
- 2. Genetics: chromosomal and multi-system disorders
- 1. Clinical evaluation and communication
- Foundation of Practice (FOP)
- Theory and Science (TAS)
- Applied Knowledge in Practice (AKP)
- Clinical
- Development
- Communication
- History
- General Pediatrics Content Outline - D15 Neurology (6%)
- General Pediatrics Content Outline - D19 Genetics (6%)
- General Pediatrics Content Outline - D21 Metabolic Disorders (3%)
- Patient Care 4: Clinical Reasoning
- Patient Care 5: Patient Management
- Medical Knowledge 1: Congenital and Genetic Disorders
- Systems-Based Practice 1: Patient Safety
- Medical Expert
- Pediatrics: Neurology - leukodystrophies and neurodegenerative disease
- Pediatrics: Medical Genetics
A three-year-old whose gait has stiffened and whose speech has thinned brings a scan showing symmetric white-matter change, and a six-year-old boy sent for behaviour problems brings a scan with a glowing splenium. In both rooms the question is the same: which leukodystrophy is this, and is there a therapy whose window is already closing? The fellowship task is to convert the magnetic-resonance-imaging pattern into a mechanism-based diagnosis and a time-aware plan that does not forfeit a treatable disorder to a generic degenerative label. [1] [3]
Anchor the whole topic with LEUKO - Lead with the contrasted brain MRI (the pattern names the group), Exclude cerebral adrenoleukodystrophy first because transplant is time-critical, Understand the mechanism (lysosomal, peroxisomal, hypomyelinating, astrocytopathic) to predict the gene, Know the Loes score and the transplant window, and Organise presymptomatic detection through newborn screening so disease-modifying therapy is given before symptoms begin. [1] [6]
Overview & Definition
The leukodystrophies are a group of inherited disorders in which a gene defect injures the white matter of the central nervous system - the myelinated axons and their supporting cells - producing progressive neurological dysfunction. They differ from the acquired demyelinating disorders (such as acute disseminated encephalomyelitis and multiple sclerosis) in being genetic, and they differ from the storage disorders that primarily engorge grey-matter neurons in being selective for white matter. The clinical thread that unites them is loss of previously acquired motor and cognitive skills - developmental regression driven by progressive white-matter injury. [1]
Why does white matter deserve its own diagnostic framework? Because the brain's myelinated tracts are built and maintained by specific cell types - oligodendrocytes that make myelin, lysosomes that turn it over, peroxisomes that handle very-long-chain fatty acids, and astrocytes that control the white-matter environment - and each leukodystrophy corresponds to a failure in one of these mechanisms. That correspondence is what lets a single magnetic-resonance-imaging pattern point to a mechanism, a gene, and a therapy. A myelin sheath that is made wrong, broken down wrong, inflamed, never formed, or surrounded by a sick astrocyte each produces a recognisable scan, and the scan is the entry point to the whole field. [1] [3]
What makes this group worth knowing in depth is the same principle that governs the wider field of neurodegeneration: a growing and consequential subset is treatable, and treatment works best - or only - when it is begun before the brain injury becomes irreversible. Haematopoietic stem cell transplant halts the inflammation of early cerebral adrenoleukodystrophy; gene therapy stabilises presymptomatic metachromatic leukodystrophy; and transplant can modify early Krabbe disease. None of these works once the injury is advanced, which is why the speed of recognition and the presymptomatic detection offered by newborn screening are the difference between a halted disease and a fatal one. [4] [9]
References12ShowHide
- [1]Parikh S, Bernard G, Leventer RJ, van der Knaap MS, van Hove J, Pizzino A, et al. A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies. Mol Genet Metab, 2015.PMID 25655951
- [2]Adang LA, Sherbini O, Ball L, et al. Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. Mol Genet Metab, 2017.PMID 28863857
- [3]Köhler W, Curiel J, Vanderver A Adulthood leukodystrophies. Nat Rev Neurol, 2018.PMID 29302065
- [4]Engelen M, van Ballegoij WJC, Mallack EJ, van Haelst MM, van Engelen CE, Vaz FM, et al. International Recommendations for the Diagnosis and Management of Patients With Adrenoleukodystrophy: A Consensus-Based Approach. Neurology, 2022.PMID 36175155
- [5]Moser AB, Seeger E, Raymond GV Newborn Screening for X-Linked Adrenoleukodystrophy: Past, Present, and Future. Int J Neonatal Screen, 2022.PMID 35225938
- [6]Mallack EJ, Turk BR, Yan H, et al. MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. J Inherit Metab Dis, 2021.PMID 33373467
- [7]Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial and an extension study. Lancet, 2016.PMID 27289174
- [8]Fumagalli F, Calbi V, Natali Sora MG, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomise, open-label, phase 1/2 trial and expanded access. Lancet, 2022.PMID 35065785
- [9]Adang LA, Bonkowsky JL, Boelens JJ, et al. Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States. Cytotherapy, 2024.PMID 38613540
- [10]van Voorst RJ, Schoenmakers DH, Bonkowsky JL, et al. Consensus-Based Expert Recommendations for Diagnosis and Clinical Management of Vanishing White Matter. Neurology, 2025.PMID 41232062
- [11]Dhamija R, Tobin WO, Cortelli P, et al. Clinical Practice Guidelines for the Diagnosis, Management, and Surveillance of LMNB1-Related Autosomal Dominant Leukodystrophy. Neurol Genet, 2025.PMID 40933505
- [12]Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 2013.PMID 23845948